Prognostic factors tested for association with survival
| Factor and category . | No. of patients . | No (%) of deaths . | Median survival time (mo) . | P (log rank)4-150 . | P (Wald χ)4-150 . | Relative risk . |
|---|---|---|---|---|---|---|
| Disease group | ||||||
| Untreated | 147 | 102 (69) | 7.5 | .32 | .80 | 0.96 |
| Pretreated | 76 | 57 (75) | 5.6 | — | — | |
| Initial dose of imatinib | ||||||
| 400 mg | 31 | 24 (77) | 4.5 | .40 | — | — |
| 600 mg | 192 | 135 (70) | 7.3 | — | — | |
| Age | ||||||
| < 60 y | 137 | 98 (72) | 6.3 | .72 | — | — |
| ≥ 60 y | 86 | 61 (71) | 7.2 | — | — | |
| Sex | ||||||
| Male | 124 | 94 (76) | 6.2 | .09 | — | — |
| Female | 99 | 65 (66) | 9.2 | — | — | |
| Weight | ||||||
| < 70 kg | 122 | 86 (70) | 6.3 | .72 | — | — |
| ≥ 70 kg | 101 | 73 (72) | 7.2 | — | — | |
| Hepatomegaly | ||||||
| No | 150 | 108 (72) | 6.7 | .80 | — | — |
| Yes | 73 | 51 (70) | 6.9 | — | — | |
| Splenomegaly | ||||||
| No | 89 | 67 (75) | 6.2 | .35 | — | — |
| Yes | 134 | 92 (69) | 7.2 | — | — | |
| Time since blast-crisis diagnosis | ||||||
| < 1 mo | 135 | 91 (67) | 7.5 | .07 | — | — |
| ≥ 1 mo | 88 | 68 (77) | 5.4 | — | — | |
| Hemoglobin | ||||||
| < 100 g/L | 151 | 116 (77) | 5.6 | .004 | — | — |
| ≥ 100 g/L | 72 | 43 (60) | 10.3 | — | — | |
| WBC count | ||||||
| < 50 × 109/L | 148 | 104 (70) | 7.5 | .15 | — | — |
| ≥ 50 × 109/L | 75 | 55 (73) | 6.0 | — | — | |
| Platelet count | ||||||
| < 100 × 109/L | 130 | 110 (85) | 4.5 | < .001 | < .001 | 2.60 |
| ≥ 100 × 109/L | 93 | 49 (53) | 14.5 | — | — | |
| Basophils in PB | ||||||
| < 10% | 195 | 142 (73) | 6.3 | .20 | — | — |
| ≥ 10% | 28 | 17 (61) | 8.7 | — | — | |
| Blasts in PB blood | ||||||
| < 50% | 149 | 93 (62) | 9.6 | < .001 | < .001 | 0.51 |
| ≥ 50% | 74 | 66 (89) | 4.0 | — | — | |
| Blasts in BM4-151 | ||||||
| < 50% | 94 | 54 (57) | 9.6 | < .001 | — | — |
| ≥ 50% | 106 | 89 (84) | 5.2 | — | — | |
| Other chromosomal abnormalities4-151 | ||||||
| No | 67 | 42 (63) | 10.3 | .003 | — | — |
| Yes | 111 | 86 (77) | 5.5 | — | — |
| Factor and category . | No. of patients . | No (%) of deaths . | Median survival time (mo) . | P (log rank)4-150 . | P (Wald χ)4-150 . | Relative risk . |
|---|---|---|---|---|---|---|
| Disease group | ||||||
| Untreated | 147 | 102 (69) | 7.5 | .32 | .80 | 0.96 |
| Pretreated | 76 | 57 (75) | 5.6 | — | — | |
| Initial dose of imatinib | ||||||
| 400 mg | 31 | 24 (77) | 4.5 | .40 | — | — |
| 600 mg | 192 | 135 (70) | 7.3 | — | — | |
| Age | ||||||
| < 60 y | 137 | 98 (72) | 6.3 | .72 | — | — |
| ≥ 60 y | 86 | 61 (71) | 7.2 | — | — | |
| Sex | ||||||
| Male | 124 | 94 (76) | 6.2 | .09 | — | — |
| Female | 99 | 65 (66) | 9.2 | — | — | |
| Weight | ||||||
| < 70 kg | 122 | 86 (70) | 6.3 | .72 | — | — |
| ≥ 70 kg | 101 | 73 (72) | 7.2 | — | — | |
| Hepatomegaly | ||||||
| No | 150 | 108 (72) | 6.7 | .80 | — | — |
| Yes | 73 | 51 (70) | 6.9 | — | — | |
| Splenomegaly | ||||||
| No | 89 | 67 (75) | 6.2 | .35 | — | — |
| Yes | 134 | 92 (69) | 7.2 | — | — | |
| Time since blast-crisis diagnosis | ||||||
| < 1 mo | 135 | 91 (67) | 7.5 | .07 | — | — |
| ≥ 1 mo | 88 | 68 (77) | 5.4 | — | — | |
| Hemoglobin | ||||||
| < 100 g/L | 151 | 116 (77) | 5.6 | .004 | — | — |
| ≥ 100 g/L | 72 | 43 (60) | 10.3 | — | — | |
| WBC count | ||||||
| < 50 × 109/L | 148 | 104 (70) | 7.5 | .15 | — | — |
| ≥ 50 × 109/L | 75 | 55 (73) | 6.0 | — | — | |
| Platelet count | ||||||
| < 100 × 109/L | 130 | 110 (85) | 4.5 | < .001 | < .001 | 2.60 |
| ≥ 100 × 109/L | 93 | 49 (53) | 14.5 | — | — | |
| Basophils in PB | ||||||
| < 10% | 195 | 142 (73) | 6.3 | .20 | — | — |
| ≥ 10% | 28 | 17 (61) | 8.7 | — | — | |
| Blasts in PB blood | ||||||
| < 50% | 149 | 93 (62) | 9.6 | < .001 | < .001 | 0.51 |
| ≥ 50% | 74 | 66 (89) | 4.0 | — | — | |
| Blasts in BM4-151 | ||||||
| < 50% | 94 | 54 (57) | 9.6 | < .001 | — | — |
| ≥ 50% | 106 | 89 (84) | 5.2 | — | — | |
| Other chromosomal abnormalities4-151 | ||||||
| No | 67 | 42 (63) | 10.3 | .003 | — | — |
| Yes | 111 | 86 (77) | 5.5 | — | — |
WBC indicates white blood cell; PB, peripheral blood; and BM, bone marrow.
Results for 223 patients with available data are shown for univariate (log rank) analysis and multivariate (Wald χ) analysis. Factors significant at P < .2 in univariate analysis were included in the multivariate model. Factors in the multivariate model were sequentially removed in order of least significance until the final model included only factors showing an effect withP < .1.
Multivariate analysis was limited to patients with available data for all prognostic factors.